News from orexigen therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 19, 2014, 07:19 ET

Orexigen's Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European Union

 Orexigen Therapeutics (NASDAQ: OREX) announced today that the Committee for Medicinal Products For Human Use (CHMP) of the European Medicines...

Nov 26, 2014, 08:30 ET

Orexigen Therapeutics to Present at the Piper Jaffray Healthcare Conference

 Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Piper...

Nov 21, 2014, 08:00 ET

Orexigen Announces Allowance of New U.S. Patent for Contrave® (naltrexone HCl / bupropion HCl extended release)

 Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the Company has received a notice of allowance from the U.S. Patent and...

Nov 10, 2014, 07:00 ET

Orexigen Therapeutics Reports Results for the Third Quarter Ended September 30, 2014

 Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced results for...

Nov 06, 2014, 16:30 ET

Orexigen Therapeutics to Present at the Credit Suisse Healthcare Conference

Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Credit Suisse...

Nov 04, 2014, 16:15 ET

Orexigen Therapeutics to Host Third Quarter 2014 Financial Results Conference Call and Webcast

Orexigen® Therapeutics, Inc. (Nasdaq: OREX) will announce financial results for the third quarter 2014, on Monday, November 10, 2014 before...

Oct 31, 2014, 08:30 ET

Orexigen Announces Contrave® (naltrexone HCI and bupropion HCI extended release) Data Presentations at the ObesityWeek Meeting in Boston

Orexigen Therapeutics (NASDAQ: OREX) today announced three Contrave® (naltrexone HCI and bupropion HCI) and two disease awareness abstracts...

Oct 15, 2014, 08:30 ET

Milestone Payments Earned by Orexigen Total $100 Million as Contrave® (naltrexone HCI and bupropion HCI extended release) is Shipped to Wholesalers in Preparation for Commercial Launch

Orexigen Therapeutics, Inc. (Nasdaq:OREX) today announced it has earned a $70 million milestone payment from partner Takeda Pharmaceuticals related...

Sep 16, 2014, 16:15 ET

Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference

 Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Bank of...

Sep 10, 2014, 19:46 ET

Orexigen Therapeutics to Host Conference Call and Webcast At 8:30 AM Eastern Time September 11, 2014

 Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will host a conference call...

Sep 02, 2014, 08:00 ET

Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent

Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the U.S. Patent and Trademark Office (PTO) has issued a patent related to NB32, the...

Aug 07, 2014, 07:00 ET

Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014

Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced corporate and...

Jul 31, 2014, 08:00 ET

Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast

Orexigen® Therapeutics, Inc. (Nasdaq: OREX) will announce financial results for the second quarter 2014, on Thursday, August 7, 2014 before...

Jul 30, 2014, 08:00 ET

Orexigen Receives CHMP Day 180 List of Outstanding Issues

 Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced it has received the Day 180 List of Outstanding Issues (LOI) from the European...

Jun 13, 2014, 08:30 ET

Orexigen Therapeutics to Present at the Wells Fargo Securities 2014 Healthcare Conference

 Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Wells Fargo Securities...

Jun 11, 2014, 06:30 ET

Orexigen Receives Three Month Extension of FDA NB32 Review

 Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the United States Food and Drug Administration (FDA) has extended its...

Jun 02, 2014, 08:00 ET

Orexigen Announces June 11, 2014 PDUFA Action Date for NB32

 Orexigen® Therapeutics, Inc. (Nasdaq: OREX), today announced that the United States Food and Drug Administration (FDA) has informed the...

May 09, 2014, 16:30 ET

Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2014 Health Care Conference

 Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Bank of America...

May 08, 2014, 16:01 ET

Orexigen Therapeutics Reports Corporate and Financial Results for the First Quarter Ended March 31, 2014

Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced corporate and...

May 01, 2014, 08:30 ET

Orexigen Therapeutics to Host First Quarter 2014 Financial Results Conference Call and Webcast

 Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce...